A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma

Objective response rate - Investigator assessment

Percentage of patients with complete or partial response determined by the investigator

Time frame: Up to 24-months

Complete response rate

Percentage of patients who achieve a Complete Response determined by independent review committee and investigators assessment

Time frame: Up to 24-months

Duration of response

Duration of response (the time from the date of the first occurrence of complete response or partial response to the date of progression, relapse, or death from any cause) determined by independent review committee and investigators

Time frame: Up to 24-months

Duration of complete response

Time from the date of the first occurrence of CR to the date of progression, relapse, or death from any cause determined by independent review committee and investigators.

Time frame: Up to 24-months

Progression-free survival

Progression-free survival (the time from CRG-022 infusion until the first occurrence of disease progression or relapse) determined by independent review committee and investigator assessment

Time frame: Up to 24-months

Overall Survival

Overall Survival (the period from the date of CRG-022 infusion until the date of death from any cause) documented by the Investigator.